BACKGROUND AND PURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information.
and tumor biology that can be measured serially and quantitatively are needed to identify high-risk subgroups at initial diagnosis for formulation of a personalized therapeutic strategy, to assess response to therapy, and to detect tumor recurrence without delay.
Physiology-based MR imaging modalities, such as DWI and DSC perfusion MR imaging, are used clinically to characterize tumor biology beyond structural abnormalities. 11 A recently published report suggests a significant correlation between DWI-derived ADC values and clinical outcomes of immunocompetent patients with PCNSL treated with high-dose methotrexate. Specifically, pretherapeutic minimum ADC values Ͻ384 ϫ 10 Ϫ6 mm 2 /s within enhancing tumor were predictive of shorter progression-free and overall survival. 12 Although there are no published data on DSC perfusion MR imaging and prognosis in patients with PCNSL, there are several studies that have demonstrated the value of rCBV as a predictor of grade and prognosis in gliomas. [13] [14] [15] [16] The purpose of our study was to confirm the validity of ADC measurement as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information.
MATERIALS AND METHODS

Patient Population
Twenty-five patients treated at our institution between June 2001 and July 2009 were selected for this retrospective study on the basis of the following criteria: histopathologic diagnosis of B-cell PCNSL as defined by the World Health Organization; negative immunodeficiency virus status; and absence of disease outside the CNS based on CT scans of the chest, abdomen, and pelvis. All patients had a pathologic diagnosis of large B-cell CNS lymphoma and received identical methotrexate-based induction chemotherapy treatment. Of 121 patients who met the inclusion criteria for this investigation, 25 had both diffusion and perfusion MR imaging available for analysis before their diagnostic biopsy. Of the 25, 15 were women and 10 were men. The average performance score at pretherapy baseline was 69.2 with a range of 50 -100.
The ) were administered every 14 -21 days as consolidation therapy. Patients who achieved a partial response, defined as an interval decrease in the contrastenhancing lesion, or who exhibited disease progression, defined by an increase in contrast-enhancing lesion volume or development of new enhancing lesions on follow-up MR imaging, were offered high-dose chemotherapy including methotrexate or whole-brain irradiation as salvage therapy. All patients with PCNSL included in this study underwent restaging with follow-up MR imaging within 5 cycles of methotrexate chemotherapy. 2 The clinical performance score, the Karnofsky Performance Score, was assessed at pretherapy baseline evaluation.
MR Imaging Protocol
The imaging protocols consisted of preoperative MR imaging performed on a 1.5T clinical scanner (Signa Horizon; GE Healthcare, Milwaukee, Wisconsin). The MR imaging protocol was as follows: 3-plane localizer, sagittal T1-weighted spin-echo (TR/TE, 600/17 ms), axial 3D T2-weighted fast spin-echo (TR/TE, 3000/ 102 ms), axial FLAIR (TR/TE/TI, 10,000/148/2200 ms), axial DWI (TR/TE, 10,000/99 ms; section thickness/intersection gap, 5/0 mm; matrix size, 256 ϫ 256; FOV, 24 cm; 3 orthogonal diffusion gradient direction; b-values, 0 and 1000 s/mm 2 ) acquired in the transverse plane covering the whole brain, DSC perfusion MR imaging, contrast-enhanced 3D spoiled gradient-recalled T1-weighted imaging (TR/TE, 34/8 ms; section thickness/intersection gap, 1.5/0 mm), and axial T1-weighted postcontrast spinecho imaging (TR/TE, 500/20 ms).
The standard DSC perfusion MR imaging protocol (TR/TE, 1250/54; flip angle 35°) at our institution was used to acquire a series of gradient-echo echo-planar images immediately before, during, and after a bolus injection of gadolinium diethylene triamine pentaacetic acid (Magnevist; Bayer Healthcare, Wayne, New Jersey). Eight axial 4-mm-thick sections were used to cover the entire tumor volume, as determined with T2-weighted FLAIR images. The first 10 echo-planar acquisitions were performed before gadolinium diethylene triamine pentaacetic acid (0.1 mmol/Kg body weight) was injected intravenously by using an MR imaging-compatible power injector (Spectris Solaris; MedRad, Indianola, Pennsylvania) at a rate of 4 -5 mL/s through a 18-or 20-ga angiocatherer and followed immediately by a 20-mL continuous saline flush. A multisection image set was obtained every 1.25 seconds before, during, and after the first pass of contrast agent until images were obtained at 60 time points.
MR Image Processing
The contrast-enhanced 3D spoiled gradient-recalled images and raw diffusion data were transferred to a commercially available workstation, aligned to the same axial location, and processed by using FuncTool software and the Advantage workstation (GE Healthcare). ADC maps were calculated on a voxel-by-voxel basis from the diffusion imaging sets. ADC measurements of the contrast-enhancing tumor volume were measured. The average ADC min values in units of 10 Ϫ6 mm 2 /s for all ROIs were calculated. The investigator responsible for production of the region of interest was blinded to pathologic and clinical outcome (F.E.V.). All ROIs were approved by an attending neuroradiologist certified by the American Board of Radiology with a Certificate of Added Qualification in neuroradiology (S.C.).
The raw data of T2*-weighted DSC perfusion MR images were transferred to the same workstation as mentioned above. rCBV maps were derived by using the methods published previously. 17 Contrast-enhanced 3D spoiled gradient-recalled images with ROIs of enhancing tumor were aligned with rCBV maps by using the aforementioned image-processing software. In addition, one 50-mm 2 region of interest was manually drawn around the enhancing region with the higher CBV for each transaxial section. A 50-mm 2 region of interest within the contralateral normal-appearing white matter for each transaxial section was used to standardize the CBV measurements (rCBV mean and rCBV min ).
Statistical Analysis
The ADC min group was stratified into low ADC min (Ͻ 384) and high ADC min (Ն384) subgroups. The rCBV mean group was stratified into low rCBV mean (Ͻ1.43) and high rCBV mean (Ն1.43) subgroups by using a receiver operating characteristic analysis. Similar analysis for the rCBV min yielded a low rCBV min subgroup (Ͻ0.56) and a high rCBV min subgroup (Ն0.56).
Using the Wilcoxon rank sum test, we performed multiplecomparison analysis among the 4 groups (high ADC/high rCBV, high ADC/low rCBV, low ADC/high rCBV, and low ADC/low rCBV). Univariate analyses were performed comparing patient age at diagnosis, CEL volume, edema volume, ADC values, and rCBV values.
Two clinical end points were measured in months: OS and PFS, defined as the time from initiation of therapy to death and to the first recurrence, respectively. A single covariate survival analysis was performed by using a logrank test. A Cox proportional hazards model was used for multivariable survival analysis. A P value Ͻ.05 was considered to indicate a significant difference between groups.
RESULTS
Anatomic Tumor Burden at Pretherapy Baseline Does Not Predict Clinical Outcome
The 
Lower Pretherapy Baseline ADC min Measurements Predict Shorter Survival
Within the patient cohort, we identified a wide range (133-1010 ϫ 10 Ϫ6 mm 2 /s) of intertumoral variability in pretherapy ADC min values. Seven of the 25 patients included in this study had an ADC min Ͻ 384 within enhancing regions and were assigned to the low ADC min subgroup. The remaining 18 patients (ADC min Ն 384) were designated as the high ADC min subgroup. As shown in Fig 1 , patients in the low ADC min subgroup had a greatly increased risk of both progression (P Ͻ .01 logrank test, hazard ratio ϭ 0.24; Fig 1D) and death (P ϭ 0.02, hazard ratio ϭ 0.29; Fig  1A) compared with the high ADC min group. Mean PFS and mean OS were significantly shorter in the low ADC min group versus the high ADC min group (P ϭ .04 and P ϭ .05, respectively).
Lower Pretherapy Baseline rCBV mean and rCBV min Measurements Predict Adverse Outcome
Ten of the 25 patients in the study with rCBV mean values Ͻ1.43 were assigned to the low rCBV mean subgroup, and the remaining 15 patients with rCBV mean Ն 1.43 were designated as the high rCBV mean subgroup. Patients in the low rCBV mean subgroup had increased risk for both rapid progression (P ϭ .03 logrank test, hazard ratio ϭ 0.28; Fig 1E) and death (P ϭ .03 logrank test, hazard ratio ϭ 0.30; Fig 1B) .
Eighteen of the 25 patients had rCBV min values Ͻ 0.56 and were designated the low rCBV min subgroup, and the remaining 7 patients (rCBV min Ն 0.56) were assigned to the high rCBV min subgroup. When patient outcome was stratified by rCBV min , the low subgroup had increased risk for rapid progression (P Ͻ .01, logrank test; Fig 1F) and death (P ϭ .01, logrank test; Fig 1C) .
Combined ADC-rCBV Groups Are Predictive of Outcomes in Which the Low ADC-low rCBV Group Has the Worst Prognosis
To evaluate the potential additive effects of ADC and rCBV stratification methods, we grouped patient cohorts by using a combined stratification method. Figure 2 illustrates survival difference among different combinations of the ADC-rCBV cohort, in which patients in the low ADC-low rCBV group had the greatest risk for both rapid disease progression (P Ͻ .01, logrank test) and death (P Ͻ .01, logrank test).
The PFS outcomes (Fig 2C, -D) were observed to cluster into nonbimodal cohorts, while the overall survival outcomes (Fig 2A,  -B ) were observed to cluster into bimodal cohorts for both categorization strategies.
When we compared the combined variables with each individual variable, the overall survival is better stratified into high and Ϫ6 mm 2 /s, the difference in clinical outcomes between the 2 groups was highly significant, in that the low-risk group had a greater than 2-fold increase in OS and an almost 3-fold increase in PFS compared with the high-risk group. The exact biologic or molecular correlate of ADC measurement in PCNSL remains unclear. Previous studies have shown significant inverse correlation between tumor cell attenuation and ADC values in PCNSL, suggesting ADC as a surrogate marker of tumor proliferation. Summarizing from numerous published reports on DWI of gliomas in which ADC values have been closely linked to tumor cell attenuation and nuclear-to-cytoplasmic ratio, [18] [19] [20] [21] one can postulate that ADC values in PCNSL are imaging surrogates of tumor cell attenuation and that lower ADC values reflect higher cellular proliferation in PCNSL, hence correlating with adverse clinical outcome.
We found those patients with low tumor First, rCBV values measure bulk vessel attenuation and thus reflect tumor angiogenesis. Second, rCBV values depend on patent vessels for delivery of intravenous gadolinium contrast agent. Therefore, low tumor rCBV values in PCNSL may signify a relative lack of tumor angiogenesis or a hypoxic microenvironment and decrease in patent vessels that are able to deliver intravenous methotrexate to the tumor bed. Our results are in agreement with the literature, in which PCNSL has been found to have hypoxic environments due to low perfusion 22 and these hypoxic environments lead to hypoxic tumors that are resistant to treatment. [23] [24] [25] From further stratification based on a combination of ADC-rCBV values, we found the strongest imaging prediction of clinical outcomes in those patients with combined low tumor ADC and low rCBV values. The high ADC-high rCBV group had very low mortality (no patients died within 5 years), while the low ADC-low rCBV group had 100% mortality within 2 years (Fig 2A, -B) . This new stratification suggests that the prognostic value of each imaging variable is additive and synergistic, in that the combination of both variables best predicted the worst prognostic subgroup of patients with PCNSL.
The results of our study have potentially high clinical impact in the treatment and management of patients with PCNSL. Noninvasive pretherapeutic imaging biomarkers that can accurately categorize patients into different risk groups of methotrexate-based chemotherapy could greatly facilitate clinical decision-making, allowing the initiation of individualized second-line salvage therapies, which may result in improved clinical outcome. [26] [27] [28] [29] While ADC may signal a subtype of PCNSL that is more aggressive as demonstrated by cellularity, 12 our rCBV measure may help predict which tumors would be less treatable by chemotherapy due to lower perfusion. Our study had several limitations. The results of our study may be influenced by its modest sample size and retrospective nature. Second, due to the paucity of available tumor-tissue samples, we were unable to correlate the rCBV measurements observed to histopathologic standards of tumor angiogenesis and hypoxia.
CONCLUSIONS
Our study further supports the important role of ADC measurement as a prognostic biomarker in immunocompetent patients with PCNSL in which the lower ADC measurement at pretherapy baseline indicates shorter overall survival. In addition, we present the first evidence of rCBV measurement as a potential prognostic biomarker in patients with PCNSL, in which lower value is associated with adverse prognosis. The predictive power of adverse outcome is even greater when risk stratification is based on combined low ADC and low rCBV values, suggesting the additive and complementary role of diffusion and perfusion MR imaging as prognostic biomarkers in patients with PCNSL.
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